TIMOTHY RODGERS
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology
- Where
- PROSPER, TX
- NPI
- 1255395067
- Received
- $35,008 in 484 records, 2019 to 2025 ($11,692 general, $23,315 research)
- As principal investigator
- $951,959 of research payments to others in 321 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 92 | $1,805 |
| 2024 | General payment | 82 | $1,750 |
| 2023 | General payment | 69 | $2,925 |
| 2023 | Research payment | 1 | $5,750 |
| 2022 | General payment | 62 | $1,518 |
| 2022 | Research payment | 1 | $31 |
| 2021 | General payment | 47 | $969 |
| 2021 | Research payment | 2 | $5,172 |
| 2020 | General payment | 45 | $868 |
| 2020 | Research payment | 2 | $7,102 |
| 2019 | General payment | 79 | $1,853 |
| 2019 | Research payment | 2 | $5,260 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 8 | $23,315 |
| Food and Beverage | 470 | $10,611 |
| Travel and Lodging | 3 | $969 |
| Education | 3 | $111 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | Galderma Laboratories, L.P. | $16 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-16 | MAYNE PHARMA COMMERCIAL LLC | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-16 | MAYNE PHARMA COMMERCIAL LLC | $0 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-16 | MAYNE PHARMA COMMERCIAL LLC | $0 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-11 | Botanix SB Inc | $29 | Food and Beverage | In-kind items and services | SOFDRA Drug, DERMATOLOGY | 2025 | |
| 2025-12-10 | LEO Pharma Inc. | $22 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-12-09 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-08 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-12-04 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-11-24 | Galderma Laboratories, L.P. | $14 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-19 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-14 | LEO Pharma Inc. | $23 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-13 | Arcutis Biotherapeutics, Inc. | $24 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-12 | Galderma Laboratories, L.P. | $7 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-11 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-10 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-06 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-04 | Arcutis Biotherapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-03 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-30 | MAYNE PHARMA COMMERCIAL LLC | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-29 | Cipher Pharmaceuticals US LLC | $22 | Food and Beverage | Cash or cash equivalent | Natroba Drug, Antiparasitic | 2025 | |
| 2025-10-28 | Regeneron Healthcare Solutions, Inc. | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-28 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-10-27 | Janssen Biotech, Inc. | $16 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-23 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-17 | Galderma Laboratories, L.P. | $6 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-14 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-07 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-03 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-09-30 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-30 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-24 | Galderma Laboratories, L.P. | $14 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-16 | UCB, Inc. | $28 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-15 | Arcutis Biotherapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-10 | Janssen Biotech, Inc. | $36 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-09 | Botanix SB Inc | $14 | Food and Beverage | In-kind items and services | SOFDRA Drug, DERMATOLOGY | 2025 | |
| 2025-09-03 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-27 | Incyte Corporation | $14 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-08-25 | SUN PHARMACEUTICAL INDUSTRIES INC. | $30 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-08-25 | Janssen Biotech, Inc. | $23 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-21 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-13 | Regeneron Healthcare Solutions, Inc. | $35 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-12 | Galderma Laboratories, L.P. | $13 | Food and Beverage | In-kind items and services | AKLIEF Drug, ACNE | 2025 | |
| 2025-08-11 | Amgen Inc. | $28 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-01 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-30 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-07-29 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-07-28 | LEO Pharma Inc. | $18 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-07-24 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-23 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-15 | Botanix SB Inc | $18 | Food and Beverage | In-kind items and services | SOFDRA Drug, DERMATOLOGY | 2025 | |
| 2025-07-11 | Galderma Laboratories, L.P. | $6 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-07 | Amgen Inc. | $27 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-07-01 | UCB, Inc. | $26 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-06-24 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-06-24 | Galderma Laboratories, L.P. | $3 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-06-18 | Botanix SB Inc | $21 | Food and Beverage | In-kind items and services | SOFDRA Drug, DERMATOLOGY | 2025 | |
| 2025-06-17 | Arcutis Biotherapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-11 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-06-10 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-05-21 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-20 | Arcutis Biotherapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-05-16 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-05-15 | Amgen Inc. | $25 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-05-07 | Arcutis Biotherapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-05-06 | ABBVIE INC. | $123 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-05-01 | LEO Pharma Inc. | $22 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-05-01 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-04-24 | Regeneron Healthcare Solutions, Inc. | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-23 | Galderma Laboratories, L.P. | $14 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-04-22 | Amgen Inc. | $28 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-04-17 | Arcutis Biotherapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-04-14 | ABBVIE INC. | $9 | Education | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-04-10 | Amgen Inc. | $33 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-04-10 | Botanix SB Inc | $24 | Food and Beverage | In-kind items and services | SOFDRA Drug, DERMATOLOGY | 2025 | |
| 2025-03-25 | Arcutis Biotherapeutics, Inc. | $22 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-03-20 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-03-12 | Organon Llc | $2 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-03-11 | Amgen Inc. | $31 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-03-06 | Biofrontera Inc. | $20 | Food and Beverage | In-kind items and services | AMELUZ Drug, DERMATOLOGY | 2025 | |
| 2025-03-03 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-27 | Galderma Laboratories, L.P. | $6 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-02-26 | Arcutis Biotherapeutics, Inc. | $22 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-02-18 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-11 | Amgen Inc. | $25 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-02-06 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-04 | UCB, Inc. | $18 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-02-03 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-01-30 | LEO Pharma Inc. | $20 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-01-23 | Galderma Laboratories, L.P. | $35 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-01-21 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-01-16 | Arcutis Biotherapeutics, Inc. | $24 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2024-12-18 | Arcutis Biotherapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2024 | |
| 2024-12-12 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-12-10 | Amgen Inc. | $24 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-12-09 | Janssen Biotech, Inc. | $35 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-12-09 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-12-05 | Dermavant Sciences, Inc. | $13 | Food and Beverage | In-kind items and services | VTAMA Drug, DERMATOLOGY | 2024 | |
| 2024-12-04 | SUN PHARMACEUTICAL INDUSTRIES INC. | $26 | Food and Beverage | In-kind items and services | Winlevi Drug, Dermatology | 2024 | |
| 2024-12-02 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-11-21 | UCB, Inc. | $20 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2024 | |
| 2024-11-20 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2024 | |
| 2024-11-14 | E.R. Squibb & Sons, L.L.C. | $24 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2024 | |
| 2024-11-13 | Arcutis Biotherapeutics, Inc. | $17 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2024 | |
| 2024-11-06 | Amgen Inc. | $27 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-10-31 | E.R. Squibb & Sons, L.L.C. | $21 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2024 | |
| 2024-10-30 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-10-28 | Lilly USA, LLC | $27 | Food and Beverage | In-kind items and services | OLUMIANT Drug, Immunology | 2024 | |
| 2024-10-24 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2024 | |
| 2024-10-17 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-10 | Amgen Inc. | $29 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-10-08 | Incyte Corporation | $17 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2024 | |
| 2024-10-02 | Almirall LLC | $19 | Food and Beverage | In-kind items and services | Klisyri Drug, Dermatology | 2024 | |
| 2024-10-01 | Novartis Pharmaceuticals Corporation | $30 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2024 | |
| 2024-09-30 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-09-26 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-09-25 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-09-23 | Galderma Laboratories, L.P. | $15 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-19 | Amgen Inc. | $26 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-09-18 | SUN PHARMACEUTICAL INDUSTRIES INC. | $18 | Food and Beverage | In-kind items and services | BLU-U Medical Supply, Dermatology | 2024 | |
| 2024-09-17 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-09-12 | LEO Pharma Inc. | $28 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2024 | |
| 2024-09-12 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2024 | |
| 2024-09-10 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-09-09 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-09-05 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2024 | |
| 2024-09-04 | Arcutis Biotherapeutics, Inc. | $24 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2024 | |
| 2024-08-29 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2024 | |
| 2024-08-28 | Janssen Biotech, Inc. | $15 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-08-22 | Arcutis Biotherapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2024 | |
| 2024-08-21 | Amgen Inc. | $31 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-08-19 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-08-12 | Novartis Pharmaceuticals Corporation | $26 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-07 | Incyte Corporation | $22 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2024 | |
| 2024-08-02 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-08-01 | Regeneron Healthcare Solutions, Inc. | $36 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-07-29 | Novartis Pharmaceuticals Corporation | $33 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2024 | |
| 2024-07-25 | Amgen Inc. | $23 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-07-22 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2024 | |
| 2024-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | SPEVIGO Drug, IMMUNOLOGY | 2024 | |
| 2024-07-16 | Janssen Biotech, Inc. | $22 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-07-10 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-07-09 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-06-26 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-06-25 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-06-24 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-20 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-06-20 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-06-17 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-06-13 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-05-28 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-05-21 | UCB, Inc. | $16 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2024 | |
| 2024-05-01 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-04-24 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-23 | Novartis Pharmaceuticals Corporation | $31 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2024 | |
| 2024-04-22 | MIMEDX Group, Inc. | $20 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-18 | Amgen Inc. | $29 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-04-09 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-03-28 | Incyte Corporation | $21 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2024 | |
| 2024-03-19 | Amgen Inc. | $23 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-03-08 | Janssen Biotech, Inc. | $35 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-03-01 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-02-27 | Lilly USA, LLC | $24 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2024 | |
| 2024-02-22 | Regeneron Healthcare Solutions, Inc. | $34 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-02-20 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2024 | |
| 2024-02-15 | Amgen Inc. | $24 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-02-08 | Novartis Pharmaceuticals Corporation | $34 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2024 | |
| 2024-02-06 | Biofrontera Inc. | $24 | Food and Beverage | Cash or cash equivalent | AMELUZ Drug, DERMATOLOGY | 2024 | |
| 2024-02-02 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2024 | |
| 2024-02-01 | PFIZER INC. | $1 | Education | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2024 | |
| 2024-01-31 | Incyte Corporation | $19 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2024 | |
| 2024-01-23 | Almirall LLC | $17 | Food and Beverage | In-kind items and services | Seysara Drug, Dermatology | 2024 | |
| 2024-01-18 | Amgen Inc. | $25 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-01-17 | Kerecis Limited | $20 | Food and Beverage | Cash or cash equivalent | Kerecis Omega3 SurgiClose Device, Wound Care | 2024 | |
| 2023-12-14 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2023 | |
| 2023-12-12 | SUN PHARMACEUTICAL INDUSTRIES INC. | $37 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2023 | |
| 2023-12-11 | Janssen Biotech, Inc. | $99 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2023 | |
| 2023-12-04 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-12-04 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-27 | Incyte Corporation | $18 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-11-22 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2023 | |
| 2023-11-16 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-11-16 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-11-14 | Amgen Inc. | $24 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2023 | |
| 2023-11-07 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2023 | |
| 2023-11-06 | SUN PHARMACEUTICAL INDUSTRIES INC. | $33 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2023 | |
| 2023-11-01 | Incyte Corporation | $14 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2023 | |
| 2023-10-31 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-10-25 | Janssen Biotech, Inc. | $33 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2023 | |
| 2023-10-20 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-10-19 | Janssen Biotech, Inc. | $14 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2023 | |
| 2023-10-10 | SUN PHARMACEUTICAL INDUSTRIES INC. | $18 | Food and Beverage | In-kind items and services | BLU-U Medical Supply, Dermatology | 2023 | |
| 2023-10-05 | PFIZER INC. | $5,750 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE P | 2023 |
| 2023-10-04 | Regeneron Healthcare Solutions, Inc. | $38 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2023 | |
| 2023-09-26 | Regeneron Healthcare Solutions, Inc. | $31 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2023 | |
| 2023-09-25 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2023 | |
| 2023-09-21 | Arcutis Biotherapeutics, Inc. | $17 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-14 | Biofrontera Inc. | $23 | Food and Beverage | Cash or cash equivalent | AMELUZ Drug, DERMATOLOGY | 2023 | |
| 2023-09-06 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2023 | |
| 2023-08-30 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 |
The latest 200 records of 484.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-16 | PFIZER INC. | North Texas Center For Clinical Research | $1,995 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-12-11 | PFIZER INC. | North Texas Center For Clinical Research | $2,128 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE P | 2025 |
| 2025-12-11 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $5,000 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-12-11 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,000 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-12-11 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,500 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-12-11 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,000 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-12-01 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $5,000 | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participant | 2025 |
| 2025-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | NORTH TEXAS CENTER FOR CLINICA | $206 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2025 |
| 2025-12-01 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,000 | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participant | 2025 |
| 2025-12-01 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,000 | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participant | 2025 |
| 2025-12-01 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,500 | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participant | 2025 |
| 2025-11-26 | PFIZER INC. | North Texas Center For Clinical Research | $5,117 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-11-06 | PFIZER INC. | North Texas Center For Clinical Research | $12,366 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE P | 2025 |
| 2025-11-04 | PFIZER INC. | North Texas Center For Clinical Research | $5,584 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | NORTH TEXAS CENTER FOR CLINICA | $1,858 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-10-09 | PFIZER INC. | North Texas Center For Clinical Research | $2,542 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE P | 2025 |
| 2025-10-09 | PFIZER INC. | North Texas Center For Clinical Research | $3,200 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-09-24 | PFIZER INC. | North Texas Center For Clinical Research | $6,630 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-09-03 | Takeda Pharmaceuticals U.S.A., Inc. | NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC | $1,593 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-09-03 | PFIZER INC. | North Texas Center For Clinical Research | $8,317 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-08-05 | PFIZER INC. | North Texas Center For Clinical Research | $5,407 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-08-01 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,637 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-08-01 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $856 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-07-23 | Takeda Pharmaceuticals U.S.A., Inc. | NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC | $1,755 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-07-23 | Takeda Pharmaceuticals U.S.A., Inc. | NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC | $4,181 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-07-23 | Takeda Pharmaceuticals U.S.A., Inc. | NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC | $1,800 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-07-11 | PFIZER INC. | North Texas Center For Clinical Research | $10,404 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-07-09 | Takeda Pharmaceuticals U.S.A., Inc. | NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC | $2,888 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2025 |
| 2025-07-07 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $991 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-07-07 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,350 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-06-20 | SANOFI US SERVICES INC. | North Texas Center For Clinical Research | $1,000 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2025-06-13 | Takeda Pharmaceuticals U.S.A., Inc. | NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC | $2,076 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-06-04 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $991 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-06-04 | Takeda Pharmaceuticals U.S.A., Inc. | NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC | $2,304 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2025 |
| 2025-06-04 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $2,198 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-06-04 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,458 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-06-04 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $2,209 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-06-04 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $2,209 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-06-04 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $343 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-06-04 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,086 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-29 | PFIZER INC. | North Texas Center For Clinical Research | $4,883 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-05-28 | Eli Lilly and Company | NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC | $8,673 | A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE | 2025 |
| 2025-05-06 | PFIZER INC. | North Texas Center For Clinical Research | $1,682 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $120 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $32 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $32 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $163 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,914 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $58 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $58 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $15 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $2,209 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $32 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-05-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,565 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-09 | Takeda Pharmaceuticals U.S.A., Inc. | NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC | $6,450 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2025 |
| 2025-04-08 | PFIZER INC. | North Texas Center For Clinical Research | $3,157 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $32 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $32 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $32 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $2 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $58 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $3 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,611 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $120 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $58 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $609 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-04-02 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $32 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-22 | PFIZER INC. | North Texas Center For Clinical Research | $7,529 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF0726 | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $25 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $343 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $2,198 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,458 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $991 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $856 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $1,914 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $2,252 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $991 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $2,252 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-03-05 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $991 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $32 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $22 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $22 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $15 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $91 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $22 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $190 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $13 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $9 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $5 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $117 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $16 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $64 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $22 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $54 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $29 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $16 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
| 2025-02-06 | Incyte Corporation | NORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR | $58 | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Prosper, TX, county Collin County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Prosper, TX | County Collin County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 37,869 | 1,163,337 | 30,188,424 |
| Population, 2020 census P1 | 30,174 | 1,064,465 | 29,145,505 |
| Median age B01002 | 37.6 | 37.3 | 35.6 |
| Under 18 B01001 | 32.7% | 24.7% | 25.0% |
| 65 and over B01001 | 9.2% | 11.6% | 13.4% |
| Households B11001 | 11,239 | 416,646 | 10,992,816 |
| Foreign born B05002 | 16.9% | 23.3% | 17.6% |
| Median household income B19013 | $195,281 | $121,600 | $78,476 |
| Median family income B19113 | $207,680 | $145,862 | $94,599 |
| Per capita income B19301 | $72,601 | $57,056 | $40,752 |
| Poverty rate B17001 | 5.5% | 6.2% | 13.8% |
| Unemployment rate B23025 | 5.6% | 4.2% | 5.3% |
| Civilian labor force B23025 | 19,043 | 642,253 | 15,233,563 |
| Mean commute (minutes) B08013 | 29.5 | 28.2 | 26.7 |
| Bachelor's degree or higher B15003 | 66.5% | 56.2% | 33.8% |
| Housing units B25001 | 11,921 | 437,396 | 12,128,515 |
| Owner-occupied B25003 | 87.9% | 64.5% | 62.6% |
| Renters B25003 | 12.1% | 35.5% | 37.4% |
| Median home value B25077 | $823,700 | $475,600 | $283,800 |
| Median gross rent B25064 | $2,176 | $1,859 | $1,403 |
| White, not Hispanic B03002 | 59.3% | 49.6% | 39.1% |
| Black B03002 | 7.2% | 10.8% | 11.9% |
| Hispanic or Latino B03002 | 12.1% | 16.1% | 39.7% |
| Asian B03002 | 14.9% | 18.7% | 5.5% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Prosper, TX.
Comments